Vesa Matti Laakso

Part of S-Group, FIM Bank Oy is a Finnish company that provides brokerage services. The company is based in Helsinki, Finland. Teri Tapio Heilala has been the CEO of the company since 2007.

UB Asset Management Ltd. (UB AM) is the investment management subsidiary of United Bankers Oyj (HEL: UNITED) in Finland. Headquartered in Helsinki, UB AM was founded in 1995 and offers expert and reliable investment services for the various needs of investors.

E. Öhman J:or Fonder AB (Öhman Fonder) is the wholly-owned fund management subsidiary of E. Öhman J:or Asset Management AB, itself a subsidiary of the Dinkelspeil family's E. Öhman J:or AB in Sweden. Formerly known as SalusAnsvar E Öhman Fonder, the firm was founded in 1947 and became E. Öhman J:or Fonder AB in 2005. Headquartered in Stockholm, Öhman Fonder offers fund management and discretionary portfolio management to institutions, insurance companies and wealthy individuals.

Part of Evli Plc, Quorum VAR Oy is a Finnish company that provides investment advice. The company is based in Helsinki, Finland. The company was founded in 2005. Marko Eino Tapio Kyyrönen has been the CEO of the company since 2013.

Optomed Software Oy develops and sells proprietary software solutions for healthcare organizations. It offers products for workflow, resource and quality management within radiological or surgical departments or any screening or follow-up program. The company was founded in 1989 and is headquartered in Espoo, Finland.

IP Finland Oy provides research and development services. It specializes in the commercialization of research-based intellectual property. The company is headquartered in Helsinki, Finland.

Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.

CanopyLAB A/S operates an educational technology platform. The company was founded by Sahra-Josephine Hjorth, Christian Skræm Juul Jensen and Esben Trier in 2015 and is headquartered in Hvidovre, Denmark.